Biosino Bio-Technology and Science Incorporation (HKG:8247)
3.100
-0.180 (-5.49%)
Sep 11, 2026, 3:22 PM HKT
HKG:8247 Revenue
Biosino Bio-Technology and Science Incorporation had revenue of 83.13M CNY in the half year ending June 30, 2026, a decrease of -37.88%. This brings the company's revenue in the last twelve months to 170.63M, down -24.19% year-over-year. In the year 2025, Biosino Bio-Technology and Science Incorporation had annual revenue of 184.29M, down -29.95%.
Revenue (ttm)
170.63M CNY
Revenue Growth
-24.19%
P/S Ratio
2.41
Revenue / Employee
442.04K CNY
Employees
386
Market Cap
474.64M HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 184.29M | -78.78M | -29.95% |
| Dec 31, 2024 | 263.07M | -26.00M | -9.00% |
| Dec 31, 2023 | 289.07M | -84.00M | -22.52% |
| Dec 31, 2022 | 373.07M | 24.85M | 7.14% |
| Dec 31, 2021 | 348.23M | 22.97M | 7.06% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| WuXi XDC Cayman | 8.02B |
| Adicon Holdings | 3.06B |
| Kindstar Globalgene Technology | 1.10B |
| Yunkang Group | 624.49M |
| Mega Genomics | 413.73M |
| Zhong Ji Longevity Science Group | 150.07M |
| King International Investment | 143.23M |
| Guanze Medical Information Industry (Holding) | 98.16M |